Reagents Search
Google Search
Sino Biological Inc. has over 10 years' experience of recombinant protein research and development, we have more than 6000 recombinant proteins in stock, covering most hot research areas, such as immune checkpoints, antibody drug targets, CAR-T cell therapy targets, Fc receptors, influenza viral proteins and cytokines.
Possessing high purity and validated bioactivity, Sino Biological recombinant proteins can support your scientific research from biopharmaceutical, protein structure, protein function, cell therapy to tool enzymes.
 |
 |
 |
||
| Immune Checkpoint Proteins Cover most of the hot cancer targets, not only PD-1/PD-L1 and CTLA-4 with approved antibody drugs, but also the ones with prospects, namely TIM-3, CD47, GITR, CEACAM1…… |
CAR-T Cell Therapy Targets Cover most of the hot cancer targets, not only PD-1/PD-L1 and CTLA-4 with approved antibody drugs, but also the ones with prospects, namely TIM-3, CD47, GITR, CEACAM1…… |
Antibody Therapeutic Targets Cover most of the hot cancer targets, not only PD-1/PD-L1 and CTLA-4 with approved antibody drugs, but also the ones with prospects, namely TIM-3, CD47, GITR, CEACAM1…… |
 |
 |
 |
||
| Cytokine & Growth Factor Cover most of the hot cancer targets, not only PD-1/PD-L1 and CTLA-4 with approved antibody drugs, but also the ones with prospects, namely TIM-3, CD47, GITR, CEACAM1…… |
Fc Receptors Cover most of the hot cancer targets, not only PD-1/PD-L1 and CTLA-4 with approved antibody drugs, but also the ones with prospects, namely TIM-3, CD47, GITR, CEACAM1…… |
Biotinylated Proteins Cover most of the hot cancer targets, not only PD-1/PD-L1 and CTLA-4 with approved antibody drugs, but also the ones with prospects, namely TIM-3, CD47, GITR, CEACAM1…… |
Fig .1 The purity of human TNFα protein (Cat. No. GMP-10602-HNAE) was >97% determined by SEC-HPLC and >96% determined by SDS-PAGE
Fig .2 The comparison of VEGF165 bioactivity from Sino Biological (EC50=1.4 ng/ml) and another brand (EC50=4 ng/ml) in cell proliferation assays using HUVEC.
Fig .3 The PD-1 (Cat. No. 10377-H03H) binding ability to PD-L2 was measured in a functional ELISA. ED50=0.94 μg/ml.
Recombinant Protein Prodution Service description
We offer one-stop services for recombinant protein production using our advanced protein expression platform technologies. Our full services include protein gene synthesis, protein codon optimization, protein expression vector design, large scale cell culture and fermentation, protein purification, and protein quality control testing. We offer significant cost saving advantages and record speed in protein expression and bulk production. We also have extensive experiences and expertise in handling various types of recombinant protein purification projects, with or without purification tags.
Sino Biological has in-house capacity to support 1000-2000 recombinant protein development and bulk production per year. We could do rapid protein expression and purification process development and conduct process scaleup studies. We can meet protein production requirements for both high-throughput and large scale bulk productions. In the last couple of years, we have successfully produced over 6000 recombinant protein bulks (in the range of milligram to gram purified proteins). The unprecedented capacity can be utilized by our customers worldwide to accelerate their basic research, structural biology, product discovery, and product development.
We are committed to become the cost-effective centralized lab for recombinant protein and monoclonal antibody bulk production to serve the life science community and biotech industry worldwide. We strive to change the way the life science community and industry generating and sourcing their proteins.
